Correspondence 0001437749-23-033195 from TALPHERA, INC. (TLPH)
TALPHERA, INC.
Date: Nov. 29, 2023 · CIK: 0001427925 · Accession: 0001437749-23-033195
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275721
Letter
RE:
acrx20231129_corresp.htm
November 29, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
AcelRx Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-275721
Ladies and Gentlemen:
AcelRx Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 30, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes John T. McKenna of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with John T. McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059.
Very truly yours,
ACELRX PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm acrx20231129_corresp.htm November 29, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-275721 Ladies and Gentlemen: AcelRx Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on November 30, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes John T. McKenna of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with John T. McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059. Very truly yours, ACELRX PHARMACEUTICALS, INC. By: /s/ Vincent J. Angotti Name: Vincent J. Angotti Title: Chief Executive Officer cc: Thomas P. McCracken, AcelRx Pharmaceuticals, Inc. John T. McKenna, Cooley LLP AcelRx Pharmaceuticals, Inc. 1850 Gateway Drive, Suite 175 San Mateo, CA 94404